Literature DB >> 17243928

Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach.

Henricus J Vermeer1, Gerard Steen, André J M Naus, Berrie Goevaerts, Pauline T Agricola, Christian H H Schoenmakers.   

Abstract

The influence of interference by hemolysis, icterus and lipemia on the results of routine chemistries may lead to wrong interpretations. On Synchron LX-20 instruments (Beckman Coulter) serum or plasma indices can be used as reliable semi-quantitative measures of the magnitude of such interference. In an article recently published in this journal, we presented the results of a multicenter study carried out in Dutch hospitals in which we determined cutoff indices for analytes above which analytically significant interference exists. Clinically significant interference cutoff indices were also derived for these analytes. In this article, we describe the handling of patient samples with clinically significant interference by hemolysis, icterus or lipemia. We investigated several possible approaches for correction of the result: dilution of the interference; mathematical correction in the case of hemolysis; treatment with ferrocyanide to destroy bilirubin; and removal of lipids in lipemic patient samples. We concluded, that mathematical correction of potassium or lactate dehydrogenase results in hemolytic samples can only be carried out if intravascular hemolysis is ruled out. Hemoglobin quantification in serial patient samples, combined with measurement of haptoglobin, represents a useful tool to rule out in vivo hemolysis. We derived an algorithm for this situation. We do not simply recommend mathematical correction, unless it is clinically acceptable. We present formulas for potassium and lactate dehydrogenase: corrected potassium=measured potassium-(hemolytic index increment x 0.14); corrected lactate dehydrogenase=measured lactate dehydrogenase-(hemolytic index increment x 75). The dilution studies indicated that dilution is only applicable for bilirubin, C-reactive protein and iron. The results of treatment with ferrocyanide were poor, and we do not recommend this method. Removal of lipids using high-speed centrifugation or LipoClear (StatSpin Inc.), a non-toxic and non-ionic polymer, is a very effective approach, although C-reactive protein, creatine kinase-MB (CK-MB) and cholesterol cannot be removed using LipoClear. For all interferants (hemoglobin, bilirubin, lipids), relatively simple algorithms are derived that can easily be implemented in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17243928     DOI: 10.1515/CCLM.2007.004

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Removing Lipemia in Serum/Plasma Samples: A Multicenter Study.

Authors:  María José Castro-Castro; Beatriz Candás-Estébanez; Margarita Esteban-Salán; Pilar Calmarza; Teresa Arrobas-Velilla; Carlos Romero-Román; Miguel Pocoví-Mieras; José Ángel Aguilar-Doreste
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

Review 2.  Hemolyzed Specimens: Major Challenge for Identifying and Rejecting Specimens in Clinical Laboratories.

Authors:  Wan Norlina Wan Azman; Julia Omar; Tan Say Koon; Tuan Salwani Tuan Ismail
Journal:  Oman Med J       Date:  2019-03

Review 3.  Lipemia: causes, interference mechanisms, detection and management.

Authors:  Nora Nikolac
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

4.  Frequency and causes of lipemia interference of clinical chemistry laboratory tests.

Authors:  Sandhya Mainali; Scott R Davis; Matthew D Krasowski
Journal:  Pract Lab Med       Date:  2017-02-03

5.  The incidence rate and influence factors of hemolysis, lipemia, icterus in fasting serum biochemistry specimens.

Authors:  Gang Tian; Yu Wu; Xinrui Jin; Zhangrui Zeng; Xiujuan Gu; Tao Li; Xiu Chen; Guangrong Li; Jinbo Liu
Journal:  PLoS One       Date:  2022-01-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.